Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
CSL Behring
CSL Behring
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Ingredients
Therapeutic: garadacimab for hereditary angioedema
Hereditary angioedema (HAE) is a rare genetic condition that can be life-threatening
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
Latest EU drug approvals span range of health issues
Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
CSL Behring expands operations to Russia
Moscow opening reinforces CSL Behring's promise to deliver therapies to patients with rare and serious diseases worldwide
Regulatory
Bleeding prevention – fibrinogen concentrate
Clinical trials are looking at the potential of fibrinogen, or Factor I, to cut the need for blood transfusions during surgery
Subscribe now